
Glaukos Corporation (NYSE:GKOS – Free Report) – Equities research analysts at Zacks Research increased their FY2026 earnings per share (EPS) estimates for shares of Glaukos in a research report issued on Wednesday, November 18th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of $0.42 per share for the year, up from their previous forecast of ($0.43). Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Glaukos’ current full-year earnings is $0.64 per share. Zacks Research also issued estimates for Glaukos’ Q4 2026 earnings at $0.27 EPS, Q1 2027 earnings at $0.09 EPS, Q2 2027 earnings at $0.17 EPS, Q3 2027 earnings at $0.33 EPS, Q4 2027 earnings at $0.65 EPS, FY2027 earnings at $1.24 EPS, Q3 2028 earnings at $0.58 EPS and FY2028 earnings at $2.24 EPS.
Glaukos (NYSE:GKOS – Get Free Report) last posted its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.57. The firm had revenue of $211.03 million during the quarter, compared to analysts’ expectations of $168.04 million. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The business’s revenue was up 58.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.16) EPS.
Read Our Latest Report on Glaukos
Glaukos Price Performance
Shares of GKOS stock opened at $237.24 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.09. The company has a market capitalization of $14.04 billion, a PE ratio of -80.69 and a beta of 0.68. The firm’s 50-day moving average is $190.92 and its two-hundred day moving average is $150.09. Glaukos has a 12 month low of $93.78 and a 12 month high of $255.18.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. grew its stake in Glaukos by 23.4% during the 3rd quarter. American Century Companies Inc. now owns 6,434 shares of the medical instruments supplier’s stock worth $1,056,000 after buying an additional 1,222 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Glaukos in the 3rd quarter valued at $200,000. EWA LLC purchased a new stake in Glaukos in the 3rd quarter valued at $218,000. Algert Global LLC raised its position in Glaukos by 43.7% in the 3rd quarter. Algert Global LLC now owns 44,361 shares of the medical instruments supplier’s stock valued at $7,284,000 after purchasing an additional 13,490 shares during the last quarter. Finally, Castleark Management LLC acquired a new stake in Glaukos during the 3rd quarter worth $7,812,000. 99.04% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Glaukos
In other news, CEO Thomas Burns sold 180,000 shares of the stock in a transaction dated Wednesday, November 18th. The shares were sold at an average price of $236.89, for a total transaction of $42,640,200.00. Following the sale, the chief executive officer owned 65,060 shares of the company’s stock, valued at approximately $15,412,063.40. This represents a 73.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 2,500 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $253.00, for a total transaction of $632,500.00. Following the sale, the director owned 37,406 shares in the company, valued at approximately $9,463,718. This trade represents a 6.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 243,278 shares of company stock valued at $58,105,705. Corporate insiders own 5.90% of the company’s stock.
Top Glaukos Stories
Investors following GKOS have been watching these stories:
- Positive Sentiment: Zacks Research lifted its FY2026 EPS estimate to $0.42 from a forecasted loss of $0.43, and its FY2027 estimate to $1.24 from $0.45. It also raised its FY2028 forecast to $2.24 from $1.70 and increased estimates for multiple quarters. The revisions suggest improved expectations for earnings growth, although they come from one research firm. Glaukos analyst estimates
- Negative Sentiment: COO Joseph Gilliam sold 861 shares for about $215,000 at $250 per share, reducing his stake by 1.19%. The sale may weigh modestly on sentiment, but he still owned 71,602 shares after the transaction. Insider sale report
Glaukos Company Profile
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Read More
- Five stocks we like better than Glaukos
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
